{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:22:45Z","timestamp":1774437765982,"version":"3.50.1"},"reference-count":22,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2017,6,19]]},"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Deficiency of \u03b1-galactosidase A (\u03b1Gal-A) in Fabry disease leads to the accumulation mainly of globotriaosylceramide (GL3) in multiple renal cell types. Glomerular podocytes are relatively resistant to clearance of GL3 inclusions by enzyme replacement therapy (ERT). Migalastat, an orally bioavailable small molecule capable of chaperoning misfolded \u03b1Gal-A to lysosomes, is approved in the European Union for the long-term treatment of patients with Fabry disease and amenable <jats:italic>GLA<\/jats:italic> (\u03b1-galactosidase A enzyme) mutations. We aimed to examine if migalastat reduces GL3 content of podocytes in Fabry disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We compared paired renal biopsies of eight adult men with amenable Fabry disease mutations at baseline and after 6 months of treatment with 150\u2009mg migalastat every other day using quantitative unbiased electron microscopic morphometric methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Migalastat treatment led to a reduction in mean total GL3 inclusion volume per podocyte in renal biopsies from baseline to 6 months. This reduction correlated precisely with reduced mean podocyte volume. There was also a direct relationship between reduction in podocyte foot process width and the reduction in mean total podocyte GL3 content following 6 months of migalastat treatment, suggestive of reduced podocyte injury.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Migalastat treatment of 6 months duration in eight male patients with Fabry disease demonstrated effective GL3 clearance from the podocyte, an important and relatively ERT-resistant glomerular cell.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmedgenet-2017-104826","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T20:20:17Z","timestamp":1501359617000},"page":"781-786","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable <i>GLA<\/i> mutations following 6 months of migalastat treatment"],"prefix":"10.1136","volume":"54","author":[{"given":"Michael","family":"Mauer","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Sokolovskiy","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay A","family":"Barth","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics, Cranbury, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P","family":"Castelli","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics, Cranbury, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadis N","family":"Williams","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics, Cranbury, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elfrida R","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics, Cranbury, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Najafian","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,7,29]]},"reference":[{"key":"2025100521211235000_54.11.781.1","first-page":"157","article-title":"Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes","volume":"81","author":"Desnick","year":"1973","journal-title":"J Lab Clin Med"},{"key":"2025100521211235000_54.11.781.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.750"},{"key":"2025100521211235000_54.11.781.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"2025100521211235000_54.11.781.4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080816"},{"key":"2025100521211235000_54.11.781.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"2025100521211235000_54.11.781.6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr420"},{"key":"2025100521211235000_54.11.781.7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100521211235000_54.11.781.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152812","article-title":"One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"2025100521211235000_54.11.781.9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"2025100521211235000_54.11.781.10","doi-asserted-by":"publisher","DOI":"10.1021\/ac404000d"},{"key":"2025100521211235000_54.11.781.11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp528"},{"key":"2025100521211235000_54.11.781.12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.484"},{"key":"2025100521211235000_54.11.781.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2818.1985.tb02607.x"},{"key":"2025100521211235000_54.11.781.14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2025100521211235000_54.11.781.15","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00478.2012"},{"key":"2025100521211235000_54.11.781.16","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.220"},{"key":"2025100521211235000_54.11.781.17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0021-9258(19)69965-5","article-title":"Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms","volume":"256","author":"Bishop","year":"1981","journal-title":"J Biol Chem"},{"key":"2025100521211235000_54.11.781.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712309105"},{"key":"2025100521211235000_54.11.781.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.05.003"},{"key":"2025100521211235000_54.11.781.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2010.03.020"},{"key":"2025100521211235000_54.11.781.21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq306"},{"key":"2025100521211235000_54.11.781.22","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv291"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2017-104826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:21:21Z","timestamp":1759724481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2017-104826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,29]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,10,23]]},"published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1136\/jmedgenet-2017-104826"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104826","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,29]]}}}